Book Reviews

Die hartJou Harl en Lewe. Deur A. J. Brink. Bl. 248. Gemustreer. RI6,95. Pretoria: Femina. 1982.The physiology of digestionExperiments and Observations on the Gastric Juice and the Physiology of Digestion. By William Beaumonr. 1st ed. 1&33. Reprinted in facsimile for the Classics ofMedicine Library, Division of Gryphon Editions Ltd, Birmingham, Alabama, 1980.Bone in Clinical Orthopaedics: A Study in ComparativeOsteology. Ed. by G. Sumner-Smith. Pp. xvi + 435. Illustrated. R94,25. Philadelphia: W. B. Saunders. 1982.Tamoxifen in breast cancerThe Role of Tamoxifen in Breast Cancer. Ed. by S. Iacobelli, M. E. Lippman and G. R. Della Cuna. Pp. xii + 124. Illustrated. 523,12. New York: Raven Press. 1982.Under the Influence. A History ofNitrous Oxide and OxygenAnaesthesia. By W. D. A. Smith. Pp. xxviii + 188. Illustrated. R33,50. London: Macmillan. 1982.Clinical internal medicine in the agedClinical Internal Medicine in the Aged. By R. W. Schrier. Pp. vii + 324. Illustrated. R61,-. Philadelphia: W. B. Saunders. 1982.Genital Infection by Chlamydia Trachomatis (Current Topicsin Infection, No. 2). By J. D. Oriel and G. L. Ridgway. Pp. viii + 144. Illustrated. R32,20. London: Edward Arnold. 1982.Placental Function Tests. By T. Chard and A. Klopper. Pp. viii + 94. Illustrated. DM42,-. Berlin: Springer-Verlag. 1982.Therapeutic Heat and Cold. 3rd ed. Ed. by J. F. Lehmann. Pp. xiv + 641. Illustrated. Baltimore: Williams & Wilkins. 1982

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study - A Randomized Clinical Trial

Background: Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown. Hypothesis/Objectives: Administration of pimobendan (0.4-0.6 mg/kg/d in divided doses) to dogs with increased heart size secondary to preclinical MMVD, not receiving other cardiovascular medications, will delay the onset of signs of CHF, cardiac-related death, or euthanasia. Animals: 360 client-owned dogs with MMVD with left atrial-to-aortic ratio >= 1.6, normalized left ventricular internal diameter in diastole >= 1.7, and vertebral heart sum >10.5. Methods: Prospective, randomized, placebo-controlled, blinded, multicenter clinical trial. Primary outcome variable was time to a composite of the onset of CHF, cardiac-related death, or euthanasia. Results: Median time to primary endpoint was 1228 days (95% CI: 856-NA) in the pimobendan group and 766 days (95% CI: 667-875) in the placebo group (P = .0038). Hazard ratio for the pimobendan group was 0.64 (95% CI: 0.47-0.87) compared with the placebo group. The benefit persisted after adjustment for other variables. Adverse events were not different between treatment groups. Dogs in the pimobendan group lived longer (median survival time was 1059 days (95% CI: 952-NA) in the pimobendan group and 902 days (95% CI: 747-1061) in the placebo group) (P = .012). Conclusions and Clinical Importance: Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated. Prolongation of preclinical period by approximately 15 months represents substantial clinical benefit

Psychometric properties of the IDS-SR30 for the assessment of depressive symptoms in spanish population

<p>Abstract</p> <p>Background</p> <p>Due to the high prevalence of depression, it is clinically relevant to improve the early identification and assessment of depressive episodes. The main objective of the present study was to examine the psychometric properties of the IDS-SR₃₀(Self-rated Inventory of Depressive Symptomatology) in a large Spanish sample of depressive patients.</p> <p>Methods</p> <p>This prospective, naturalistic, multicenter, nationwide epidemiological study conducted in Spain included 1595 adult patients (65.3% females) with a DSM-IV Major Depressive Disorder (MDD. IDS-SR₃₀and the Hamilton Depression Rating Scale (HDRS, 21 items)were administered to the sample. Data was collected during 2 routine visits. The second assessment was carried out after 10 ± 2 weeks after first assessment.</p> <p>Results</p> <p>The IDS-SR₃₀showed good internal consistency (α = 0.94) and high item total correlations (≥ 0.50) were found in 70% of the items. The convergent validity was 0.85. Results of the principal component analysis (PCA) and confirmatory factor analyses (CFA) showed that a three factor model (labelled mood/cognition, anxiety/somatic and sleep) is adequate for the current sample.</p> <p>Conclusions</p> <p>The Spanish version of the IDS-SR₃₀seems a reliable, valid and useful tool for measuring depression symptomatology in Spanish population.</p

Reducing recurrent stroke: methodology of the motivational interviewing in stroke (MIST) randomized clinical trial

Recurrent stroke is prevalent in both developed and developing countries, contributing significantly to disability and death. Recurrent stroke rates can be reduced by adequate risk factor management. However, adherence to prescribed medications and lifestyle changes recommended by physicians at discharge after stroke is poor, leading to a large number of preventable recurrent strokes. Using behavior change methods such as Motivational Interviewing early after stroke occurrence has the potential to prevent recurrent stroke

Infrared Spectral Energy Distributions of Seyfert Galaxies: Spitzer Space Telescope Observations of the 12 micron Sample of Active Galaxies

The mid-far-infrared spectral energy distributions (SEDs) of 83 active galaxies, mostly Seyfert galaxies, selected from the extended 12 micron sample are presented. The data were collected using all three instruments, IRAC, IRS, and MIPS, aboard the Spitzer Space Telescope. The IRS data were obtained in spectral mapping mode, and the photometric data from IRAC and IRS were extracted from matched, 20 arcsec diameter circular apertures. The MIPS data were obtained in SED mode, providing very low resolution spectroscopy (R ~ 20) between ~ 55 and 90 microns in a larger, 20 by 30 arcsec synthetic aperture. We further present the data from a spectral decomposition of the SEDs, including equivalent widths and fluxes of key emission lines; silicate 10 and 18 micron emission and absorption strengths; IRAC magnitudes; and mid-far infrared spectral indices. Finally, we examine the SEDs averaged within optical classifications of activity. We find that the infrared SEDs of Seyfert 1s and Seyfert 2s with hidden broad line regions (HBLR, as revealed by spectropolarimetry or other technique) are qualitatively similar, except that Seyfert 1s show silicate emission and HBLR Seyfert 2s show silicate absorption. The infrared SEDs of other classes with the 12 micron sample, including Seyfert 1.8-1.9, non-HBLR Seyfert 2 (not yet shown to hide a type 1 nucleus), LINER and HII galaxies, appear to be dominated by star-formation, as evidenced by blue IRAC colors, strong PAH emission, and strong far-infrared continuum emission, measured relative to mid-infrared continuum emission.Comment: 78 pages, 13 figure

Sinteza, in vitro antitumorsko ispitivanje i radiosenzitirajuće vrednovanje novih derivata 4-[3-(supstituiranih)tioureido]-N-(kinoksalin-2-il)benzensulfonamida

Sulfonamides and quinoxaline derivatives possess many types of biological activities and have been recently reported to show substantial antitumor activity. This paper reports the synthesis of novel thioureidosulfaquinoxaline derivatives. All the newly synthesized compounds were evaluated for their in vitro anticancer activity against a human liver cell line (HEPG2) and showed higher activity than the reference drug doxorubicin. 4-(3-(4-Ethylbenzoate)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide (9) (IC50 = 15.6 µmol L1), N-(pyridin-2-yl)-4-(3-(4-(N-quinoxalin-2-yl-sulfamoyl)phenyl)thioureido)benzene-sulfonamide (10) (IC50 = 26.8 µmol L1) and N-(quinoxalin-2-yl)-4-(3-(4-(N-thiazol-2-ylsulfamoyl)phenyl)thioureido)benzenesulfonamide (11) (IC50 = 24.4 µmol L1) were the most potent compared to doxorubicin (IC50 = 71.8 µmol L1). The most potent compounds 9, 10 and 11 were evaluated as radiosensitizing agents by subjecting the compounds to γ-irradiation (8 kGy).Derivati sulfonamida i kinoksalina imaju raznoliko biološko djelovanje, između ostalog i antitumorsko djelovanje. U radu je opisana sinteza novih derivata tioureido sulfakinoksalina. Svim novim spojevima ispitano je antitumorsko djelovanje in vitro na humanoj staničnoj liniji jetre (HEPG 2). Svi ispitani spojevi pokazuju jači učinak nego referentni lijek doksorubicin. Najjači učinak imali su 4-(3-(4-etilbenzoat)tioureido)-N-(kinoksalin-2-il)benzen-sulfonamid (9) (IC50 = 15,6 µmol L1), N-(piridin-2-il)-4-(3-(4-(N-kinoksalin-2-il-sulfamoil)fenil)tioureido)-benzen-sulfonamid (10) (IC50 = 26,8 µmol L1) i N-(kinoksalin-2-il)-4-(3-(4-(N-tiazol-2-ilsulfamoil)fenil)tioureido)benzen-sulfonamid (11) (IC50 = 24,4 µmol L1), dok je IC50 vrijednost bila 71,8 µmol L1. Najaktivniji spojevi 9, 10 i 11 evaluirani su kao radziosenzitirajuća sredstva nakon izlaganja spojeva γ-zračenju (8 kGy)

Management of major depression in outpatients attending a cancer centre: a preliminary evaluation of a multicomponent cancer nurse-delivered intervention

A novel nurse-delivered multicomponent intervention for major depressive disorder (MDD) in cancer outpatients was compared with usual care alone in a nonrandomised matched group design (n=30 per group). At the final 6-month outcome, 38.5% (95% CI, 5.4-57%) fewer patients in the intervention group still met the criteria for MDD

An ISOCAM survey through gravitationally lensing galaxy clusters

ISOCAM was used to perform a deep survey through three gravitationally lensing clusters of galaxies. Nearly seventy sq. arcmin were covered over the clusters A370, A2218 and A2390. We present maps and photometry at 6.7 & 14.3 microns, showing a total of 145 mid-IR sources and the associated source counts. The 15 micron counts reach the faintest level yet recorded. All sources have counterparts in the optical or near-IR. Models of the clusters were used to correct for the effects of lensing, which increases the sensitivity of the survey. Seven of fifteen SCUBA sources were detected at 15 microns. Five have redshift between 0.23 & 2.8, with a median of 0.9. The field sources were counted to a lensing-corrected sensitivity of 30 microJy at 15 microns, and 14 microJy at 7 microns. The counts, corrected for completeness, contamination by cluster sources and lensing, confirm and extend findings of an excess by a factor of ten in the 15 micron population with respect to source models with no evolution. Source redshifts are mostly between 0.4 and 1.5. For the counts at 7 microns, integrating from 14 microJy to 460 microJy, we resolve 0.49+/-0.2 nW.m^(-2).sr^(-1) of the infrared background light (IBL) into discrete sources. At 15 microns we include the counts from other ISOCAM surveys to integrate from 30 microJy to 50 mJy, two to three times deeper than unlensed surveys, to resolve 2.7+/-0.62 nW.m^(-2).sr^(-1) of the IBL. These values are 10% and 55%, respectively, of the upper limit to the IBL, derived from photon-photon pair production of the TeV gamma rays from BL-Lac sources on the IBL photons. However, recent detections of TeV gamma rays from the z=0.129 BL Lac H1426+428 suggest that the 15 micron background reported implies substantial absorption of TeV photons from that source.Comment: 35 pages, 17 figures, to appear in Astronomy and Astrophysics, full paper with high-resolution figures available at http://www.iso.vilspa.esa.es/science/pub/2003